328 related articles for article (PubMed ID: 26299958)
1. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
Badar T; Kantarjian HM; Nogueras-Gonzalez GM; Borthakur G; Garcia Manero G; Andreeff M; Konopleva M; Kadia TM; Daver N; Wierda WG; Luthra R; Patel K; Oran B; Champlin R; Ravandi F; Cortes JE
Am J Hematol; 2015 Nov; 90(11):1065-70. PubMed ID: 26299958
[TBL] [Abstract][Full Text] [Related]
2. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
3. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB
Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
Metzelder SK; Schroeder T; Lübbert M; Ditschkowski M; Götze K; Scholl S; Meyer RG; Dreger P; Basara N; Fey MF; Salih HR; Finck A; Pabst T; Giagounidis A; Kobbe G; Wollmer E; Finke J; Neubauer A; Burchert A
Eur J Cancer; 2017 Nov; 86():233-239. PubMed ID: 29055209
[TBL] [Abstract][Full Text] [Related]
5. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
[TBL] [Abstract][Full Text] [Related]
7. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
[TBL] [Abstract][Full Text] [Related]
8. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
Tschan-Plessl A; Halter JP; Heim D; Medinger M; Passweg JR; Gerull S
Ann Hematol; 2015 Nov; 94(11):1899-905. PubMed ID: 26233683
[TBL] [Abstract][Full Text] [Related]
10. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
[TBL] [Abstract][Full Text] [Related]
11. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
[TBL] [Abstract][Full Text] [Related]
12. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
13. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Tarlock K; Chang B; Cooper T; Gross T; Gupta S; Neudorf S; Adlard K; Ho PA; McGoldrick S; Watt T; Templeman T; Sisler I; Garee A; Thomson B; Woolfrey A; Estey E; Meshinchi S; Pollard JA
Pediatr Blood Cancer; 2015 Jun; 62(6):1048-54. PubMed ID: 25662999
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
Hu B; Vikas P; Mohty M; Savani BN
Expert Rev Hematol; 2014 Apr; 7(2):301-15. PubMed ID: 24308526
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A
Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928
[TBL] [Abstract][Full Text] [Related]
17. The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia.
Schechter T; Gassas A; Chen H; Pollard J; Meshinchi S; Zaidman I; Hitzler J; Abdelhaleem M; Ho R; Domm J; Woolfrey A; Frangoul H
Biol Blood Marrow Transplant; 2015 Jan; 21(1):172-5. PubMed ID: 25139215
[TBL] [Abstract][Full Text] [Related]
18. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.
Sengsayadeth SM; Jagasia M; Engelhardt BG; Kassim A; Strickland SA; Goodman S; Lucid C; Vnencak-Jones CL; Greer JP; Savani BN
Bone Marrow Transplant; 2012 Dec; 47(12):1535-7. PubMed ID: 22659680
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Zu YL; Zhang YL; Zhou J; Han LJ; Zhao HF; Gui RR; Hou YJ; Song YP
Zhonghua Nei Ke Za Zhi; 2016 Aug; 55(8):634-6. PubMed ID: 27480560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
